Self-identified Race and COVID-19-Associated Acute Kidney Injury and Inflammation: a Retrospective Cohort Study of Hospitalized Inner-City COVID-19 Patients

Nipith Charoenngam, MD1,2, Titilayo O. Ilori, MD, MSc3, Michael F. Holick, PhD, MD1, Natasha S. Hochberg, MD, MPH4, and Caroline M. Apovian, MD5

1Section Endocrinology, Diabetes, Nutrition and Weight Management, Department of Medicine, Boston University School of Medicine, Boston, MA, USA; 2Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 3Section of Nephrology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA; 4Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, USA; 5Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.

BACKGROUND: Black individuals have been disproportionately affected by the coronavirus disease 2019 (COVID-19). However, it remains unclear whether there are any biological factors that predispose Black patients to COVID-19-related morbidity and mortality.

OBJECTIVE: To compare in-hospital morbidity, mortality, and inflammatory marker levels between Black and White hospitalized COVID-19 patients.

DESIGN AND PARTICIPANTS: This single-center retrospective cohort study analyzed data for Black and White patients aged ≥ 18 years hospitalized with a positive SARS-CoV-2 PCR test between March 1, 2020, and August 4, 2020.

MAIN MEASURES: The exposure was self-identified race documented in the medical record. The primary outcome was in-hospital death. Secondary outcomes included intensive care unit admission, hospital morbidities, and inflammatory marker levels.

KEY RESULTS: A total of 1,424 Black and White patients were identified. The mean ± SD age was 56.1 ± 17.4 years, and 663 (44.5%) were female. There were 683 (48.0%) Black and 741 (52.0%) White patients. In the univariate analysis, Black patients had longer hospital stays (8.1 ± 10.2 vs. 6.7 ± 8.3 days, p = 0.011) and tended to have higher rates of in-hospital death (11.0% vs. 7.3%), myocardial infarction (6.9% vs. 4.5%), pulmonary embolism (PE; 5.0% vs. 2.3%), and acute kidney injury (AKI; 39.4% vs. 23.1%) than White patients (p < 0.05). However, after adjusting for potential confounders, only PE (adjusted odds ratio [aOR] 2.07, 95% CI, 1.13–3.79) and AKI (aOR 2.16, 95% CI, 1.57–2.97) were statistically significantly associated with Black race. In comparison with White patients, Black patients had statistically significantly higher peak plasma D-dimer (standardized β = 0.10), erythrocyte sedimentation rate (standardized β = 0.13), ferritin (standardized β = 0.09), and lactate dehydrogenase (standardized β = 0.11), after adjusting for potential confounders (p<0.05).

CONCLUSIONS: Black hospitalized COVID-19 patients had increased risks of developing PE and AKI and higher inflammatory marker levels compared with White patients. This observation may be explained by differences in the prevalence and severity of underlying comorbidities and other unmeasured biologic risk factors between Black and White patients. Future research is needed to investigate the mechanism of these observed differences in outcomes of severe COVID-19 infection in Black versus White patients.

INTRODUCTION

Racial disparities in health have been recognized in the USA for decades and are a major public health concern. Black individuals are more likely than White individuals to have major chronic diseases, including metabolic disorders, kidney disease, cardiovascular disease, cancers, mental illnesses, and pregnancy complications among others. This results in higher risks of morbidity and mortality. According to data from the Third National Health and Nutrition Examination Survey (NHANES III), non-Hispanic Black individuals had an approximately 2 times higher risk of all-cause mortality, 1.2 times higher risk of cardiovascular mortality, and 1.4 times neoplasm-related mortality than White individuals. Black individuals in the USA also have a threefold risk of chronic kidney disease (CKD) compared to White individuals and are more likely to have albuminuria. These differences may be explained by differences in genetics, socioeconomic status, access to care, diet, culture, and other factors and the interplay between these factors.

Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19), racial disparities in the development, severity, and outcomes of this disease have become increasingly apparent. It has been reported that Black
individuals have been disproportionately affected by the novel virus.\textsuperscript{12–16} For example, approximately three times the rate of infection and six times the rate of death were observed in counties in the USA where a large percentage of Black individuals live compared with those where a large percentage of White individuals live.\textsuperscript{11} Furthermore, according to the report by the Centers for Disease Control and Prevention in November 2020, the Black population had a 1.4 times higher number of COVID-19 patients, 3.7 times higher rate of COVID-19 hospitalization, and 2.8 times higher COVID-19 mortality rate than White, non-Hispanic populations.\textsuperscript{14}

The unequal magnitude of disease burden in the Black population is thought to be driven by higher rates of comorbidities and increased viral exposure among the Black population, which is due primarily to differences in social determinants of health.\textsuperscript{15} These include more limited health care access, higher rates of disadvantageous housing conditions, higher incarceration rates, and greater exposure to long-term care residence.\textsuperscript{17} However, it remains unclear whether there are any genetic or biological factors that predispose Black individuals to COVID-related morbidity and mortality, since some studies have demonstrated that once infected and hospitalized, there was no racial difference in mortality rates after controlling for age, sex, and underlying comorbidities.\textsuperscript{18,19}

Using information from the electronic medical record at the Boston University Medical Campus, we aimed to investigate whether there were differences in outcomes in hospitalized COVID-19 patients who self-identified as Black or White. Additionally, we aimed to identify biological and other determinants of outcomes in self-identified Black and White individuals hospitalized with COVID-19.

## METHODS

### Study Population

This is a retrospective chart review, cohort study in adult Black and White COVID-19 patients aged ≥18 years old who were hospitalized at Boston Medical Center (BMC) between March 1, 2020, and August 4, 2020. This inner-city safety net hospital is an ideal setting to perform such an evaluation as it consists of comparable numbers of Black and White patients hospitalized with COVID-19 with relatively similar socioeconomic backgrounds. All patients included in this study tested positive for SARS-CoV-2 nucleic acid testing. The study protocol was approved by the Boston University Medical Campus Institutional Review Board (H-40341)

### Study Measurements

Characteristics of patients were extracted from the BMC hospital database (electronic medical record). The following patient baseline characteristics were extracted: age, sex, self-identified race, health coverage status (commercial insurance, public insurance, and uninsured), last body mass index determination (BMI), smoking history, and alcohol use. Using data form the US Census Bureau, zip code of each patient was linked with the estimated median household income in 2019 for each zip code.\textsuperscript{20} We also recorded presence of underlying comorbidities using data from the physician diagnosis of underlying medical conditions determined by the International Classification of Disease, 10th Revision, Clinical Modification (ICD-10-CM) in the electronic medical record. These include type 2 diabetes mellitus (E11), hypertension (I10), dyslipidemia (E78), heart disease (coronary artery disease, I25, or heart failure, I50), cerebrovascular disease (I66, I67, I69, G45), asthma (J45), chronic obstructive pulmonary disease (COPD, J44), CKD, end-stage renal disease (ESRD, N18.6), proteinuria (R80), malignancy (C80), and human immunodeficiency virus (HIV) infection (B20). The most recent hemoglobin A1C (HbA1C) and outpatient blood pressure measured prior to admission were recorded to reflect control of diabetes and hypertension, respectively. The latest clinic estimated glomerular filtration rate (eGFR) measured prior to hospitalization was recorded to reflect baseline kidney function. Furthermore, we recorded in-hospital medical therapy for COVID-19, including corticosteroids, interleukin-6 antibodies, interleukin-1 receptor antagonist, and remdesivir.

Inflammatory marker levels measured at the time of hospitalization or as soon thereafter as was available (within 3 days after admission) were extracted from the hospital EMR. These included plasma D-dimer, plasma C-reactive protein, erythrocyte sedimentation rate (ESR), plasma ferritin and serum lactate dehydrogenase (LDH), absolute lymphocyte count, and absolute neutrophil count. Since inflammatory markers often change over time in acute COVID-19 infection, we also recorded and analyzed highest levels of D-dimer, ESR, CRP, ferritin, LDH, and absolute neutrophil count and lowest level of absolute lymphocyte count with the aim to minimize the confounding effect of timing of presentation. Oxygen saturation measured by pulse oximetry at the time at the time of hospitalization was also collected.

The primary outcome of this study was in-hospital death. Secondary outcomes included intensive care unit (ICU) admission, need for intubation, hospital length of stay, hypoxemia (O₂ saturation <90%), and diagnosis based on the ICD-10-CM codes of acute respiratory distress syndrome (ARDS, J80), myocardial infarction (I21), acute kidney injury (AKI, N17), severe sepsis/septic shock (R65.20, R65.21), deep venous thrombosis (I82.40), pulmonary embolism (PE, I26), and inflammatory marker levels. All hospital outcomes were derived from admission diagnosis extracted from the EMR and were validated by manual chart review.

### Statistical Analysis

Continuous variables were reported as arithmetic means with standard deviation (SD) or standard error of mean (SEM). Categorical variables were reported as number of patients with
percentages. Comparison of baseline characteristics and laboratory measurements between Black and White patients was performed using independent sample t-test for continuous parametric data, Mann-Whitney U test for continuous non-parametric data, and chi-square or Fisher's exact test for categorical data. Multivariate logistic regression was used to determine adjusted odds ratios (aORs) and 95% confidence interval (CI) that represent the association between race and outcomes with White race as the reference; multivariable models to assess predictors of inflammatory markers were also conducted. Initially, variables were subjected to univariate analysis. Covariates with a p-value of <0.2 and those with plausible biologic or behavioral relationships or previously documented to be related with the outcomes of COVID-19 were included into the model. Then, backward elimination was performed to remove insignificant variables from the models. Linear regression was applied to determine the correlation between race and inflammatory marker levels with White race as the reference group. Due to the concern of multiple testing of clinical outcomes, we define true statistical significance as the p-value of <0.01, while the p-value of <0.05 was defined as having a trend towards statistical significance. SPSS version 27 (SPSS Inc., Chicago, IL) was used to perform all statistical analysis.

RESULTS

A total of 1,478 adult hospitalized COVID-19 patients were identified from the hospital EMR between March 1, 2020, and August 4, 2020. Among them, 8 Asian patients, 18 patients of other races, and 28 patients with unavailable data on race were excluded. Finally, 1,424 Black and White patients were included in the analysis. The mean ± SD age was 56.1 ± 17.4 years and 663 (44.5%) were female (Table 1). Overall, there were 683 (48.0%) Black and 741 (52.0%) White patients. Compared to White patients, Black patients were statistically significantly older (59.5 ± 17.1 vs. 52.9 ± 17.0 years, p < 0.001) and had higher rates of presence of underlying comorbidities, uncontrolled diabetes and hypertension, and receipt of chronic medications (Supplemental Table 1), and had lower baseline eGFR (79.5 ± 36.0 vs. 83.7 ± 28.8 mL/min/1.73m², p = 0.010). In addition, a significantly lower percentage of Black patients were treated with remdesivir (3.2% vs. 6.2%, p = 0.008). In terms of the socioeconomic status, the distributions of health coverage types were similar between Black and White patients (commercial insurance: 17.7% vs. 16.2%; public insurance: 80.2% vs. 81.2%; uninsured: 1.6% vs. 1.9%, p = 0.747). We found that the estimated income based on zip code was slightly lower in Black patients compared with White patients (median: $58,105 vs. $60,579 per household in 2019, p < 0.001).

Table 1 Baseline Characteristics of Self-Identified Black and White Patients Hospitalized with COVID-19 in a Safety-Net Hospital

| Variable | All patients (N = 1424) | Black (N = 683) | White (N = 741) | p-value |
|----------|-------------------------|----------------|----------------|---------|
| Age (year) | 56.1 ± 17.4 | 59.5 ± 17.1 | 52.9 ± 17.0 | <0.001* |
| Female sex | 633 (44.5%) | 320 (46.9%) | 313 (42.2%) | 0.080 |
| Hispanic | 488 (34.3%) | 71 (10.4%) | 417 (56.4%) | <0.001* |
| Non-Hispanic | 935 (65.7%) | 612 (89.6%) | 323 (43.6%) | |
| BMI (kg/m²) | 30.2 ± 8.3 | 30.5 ± 9.2 | 30.0 ± 7.4 | 0.978 |
| Smoking history | 532 (37.4%) | 275 (40.3%) | 257 (34.7%) | 0.030* |
| Alcohol use | 445 (31.3%) | 220 (32.2%) | 225 (30.4%) | 0.453 |
| Type 2 diabetes mellitus | 460 (32.3%) | 262 (38.4%) | 198 (26.7%) | <0.001* |
| Type 2 diabetes mellitus with baseline HbA1C <7% | 349 (24.8%) | 191 (28.0%) | 158 (21.3%) | <0.001* |
| Type 2 diabetes mellitus with baseline HbA1C 7–<8% | 40 (2.8%) | 26 (3.8%) | 14 (1.9%) | |
| Type 2 diabetes mellitus with baseline HbA1C 8–<9% | 20 (1.4%) | 13 (1.9%) | 7 (0.9%) | |
| Type 2 diabetes mellitus with baseline HbA1C 9–<10% | 13 (0.9%) | 9 (1.3%) | 4 (0.5%) | |
| Type 2 diabetes mellitus with baseline HbA1C ≥10% | 38 (2.7%) | 23 (3.4%) | 15 (2.0%) | |
| Hypertension | 755 (53.0%) | 449 (65.5%) | 306 (41.3%) | <0.001* |
| Hypertension with baseline BP 130–140/80–90 mmHg | 140 (9.8%) | 92 (13.5%) | 48 (6.5%) | <0.001* |
| Hypertension with baseline BP >140/90 mmHg | 230 (16.2%) | 155 (22.7%) | 75 (10.1%) | |
| Dyslipidemia | 513 (36.0%) | 289 (42.3%) | 224 (30.2%) | <0.001* |
| Heart disease | 200 (14.0%) | 120 (17.6%) | 80 (10.8%) | <0.001* |
| Cerebrovascular disease | 57 (4.0%) | 40 (5.9%) | 17 (2.3%) | <0.001* |
| COPD | 99 (7.0%) | 44 (6.4%) | 55 (7.4%) | 0.467 |
| Asthma | 206 (14.5%) | 121 (17.7%) | 85 (11.5%) | <0.001* |
| CKD | 218 (15.3%) | 150 (22.0%) | 68 (9.2%) | <0.001* |
| Baseline eGFR (mL/min/1.73m²) | 81.7 ± 32.5 | 79.5 ± 36.0 | 83.7 ± 28.8 | 0.010 |
| ESRD | 67 (4.7%) | 44 (6.4%) | 23 (3.1%) | 0.003* |
| Proteinuria | 53 (3.7%) | 27 (4.0%) | 26 (3.5%) | 0.658 |
| Malignancy | 146 (10.3%) | 91 (13.3%) | 55 (7.4%) | <0.001* |
| HIV infection | 41 (2.9%) | 31 (4.5%) | 10 (1.3%) | <0.001* |
| In-hospital medical therapy for COVID-19 | | | | |
| Corticosteroids | 131 (9.2%) | 72 (10.5%) | 59 (8.0%) | 0.092 |
| IL-6 antibodies | 278 (19.5%) | 142 (20.8%) | 136 (18.4%) | 0.246 |
| IL-1 receptor antagonists | 48 (3.4%) | 23 (3.4%) | 25 (3.4%) | 0.995 |
| Remdesivir | 68 (4.8%) | 22 (3.2%) | 46 (6.2%) | 0.008* |
| Anticoagulants | 1207 (84.8%) | 585 (85.7%) | 622 (83.9%) | 0.369 |

Abbreviations: BMI body mass index, BP blood pressure, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, HbA1C hemoglobin A1C, HIV human immunodeficiency virus, IL-1 interleukin-1, IL-6 interleukin-6

Data were expressed as mean ± SD, median (interquartile range) or number of patients (%)

*p* denotes statistically significant difference between Black and White patients (p < 0.05)

"Patients with end-stage renal disease were excluded"
Clinical Outcomes

In the univariate analyses, Black patients tended to have higher rates of in-hospital death (11.0% vs. 7.3%, p = 0.012) and myocardial infarction (6.9% vs. 4.5%, p = 0.047), and had statistically significantly higher rates of PE (5.0% vs. 2.3%, p = 0.006) and AKI (39.4% vs. 23.1%, p <0.001) than White patients (Table 2). In addition, Black patients tended to have longer hospital stays than White patients (mean ± SD: 8.1 ± 10.2 vs. 6.7 ± 8.3 days, p = 0.011).

In multivariable models, Black patients had a statistically significantly higher odds of PE than White patients (aOR 2.07, 95% CI, 1.13–3.79; Fig. 1) after adjusting for age, sex, and presence of underlying CKD. In addition, after excluding 67 patients with pre-existing ESRD from the analysis, Black patients had a statistically significantly higher odds of AKI (aOR 2.16, 95% CI, 1.57–2.97) after adjusting for age, sex, BMI, and presence of underlying type 2 diabetes, hypertension, and baseline eGFR. No statistically significant independent association between race and other hospital outcomes was observed. Effect estimates of variables included in the multivariable models are shown in the Supplementary Table.

Inflammatory Marker Levels

In comparison with White patients, Black patients had higher initial and peak plasma D-dimer (mean ± SEM initial D-dimer: 1676.3 ± 229.5 vs. 818.0 ± 124.1 ng/mL FEU; peak D-dimer: 4189.6 ± 397.8 vs. 2117.5 ± 235.6, both p <0.001), ESR (initial ESR: 76.8 ± 1.5 vs. 62.7 ± 1.4 mm/h; peak ESR: 81.6 ± 1.5 vs. 67.2 ± 1.4, both p <0.001), plasma ferritin (initial ferritin: 1310.9 ± 141.4 vs. 801.3 ± 62.3 ng/mL; peak ferritin: 2372.9 ± 221.8 vs. 1399.6 ± 122.1, both p <0.05), and serum LDH (initial LDH: 403.1 ± 13.5 vs. 348.9 ± 8.1 U/L; peak LDH 536.6 ± 19.0 vs. 467.6 ± 18.9, both p <0.001; Figs. 2 and 3). Black patients had lower lowest absolute lymphocyte counts than White patients (0.8 ± 0.03×10^9 vs. 0.9 ± 0.03×10^9 cells/μL, p = 0.022). Subgroup analysis showed that initial ESR and plasma D-dimer, and peak ESR, plasma D-dimer, and serum LDH, were higher in Black patients than in White patients across all age and sex groups (age ≥65 and <65 years, male and female, Figs. 2 and 3). In multivariable models, Black race was associated with increased both initial and peak levels of D-dimer, ESR, ferritin, and LDH, after adjusting for potential confounders (all p <0.05; Tables 3 and 4).

Since race was associated with AKI and PE, additional analysis was performed to further investigate racial differences in inflammatory burden specifically in patients with AKI and PE. Compared with White AKI patients, Black AKI patients had higher initial plasma D-dimer (mean ± SEM: 2238.2 ± 430.3 vs. 1337.8 ± 357.5 ng/mL FEU, p = 0.048), ESR (83.3 ± 2.2 vs. 69.9 ± 2.9 mm/h, p <0.001), and serum LDH (471.6 ± 26.8 vs. 400.7 ± 24.9 U/L, p <0.001; Fig. 2). In addition, Black AKI patients had higher peak ESR than White AKI patients (88.2 ± 2.2 vs. 74.3 ± 2.9 mm/h, p <0.001; Fig. 3). No significant difference in the rate of positive proteinuria measured by urine dipstick was found between Black and White patients with AKI (21.8% vs. 23.7%, p = 0.673).

DISCUSSION

In this retrospective study, we compared hospital outcomes and inflammatory marker levels between Black and White hospitalized COVID-19 patients at BMC, the largest safety-net hospital in New England.21 We found in the multivariate analysis that AKI and PE were associated with self-identified Black race after adjustment for potential confounders. In addition, we observed higher levels of inflammatory markers (ESR, D-dimer, ferritin, and LDH) in Black patients compared with White patients, suggesting racial differences in inflammatory burden from COVID-19. We also found in the univariate analysis that Black patients tended to have higher rates of in-hospital death and myocardial infarction than White patients. However, these outcomes were no longer associated with Black race after adjustment for potential confounders such as age and underlying comorbidities, indicating that the difference found in the univariate analysis is likely due to the fact that Black patients were older and had higher rates of pre-existing comorbidities and receipt of chronic medications that might affect the pathogenesis and outcomes of COVID-19.22,23 In addition, a smaller proportion of them were treated with remdesivir.

It has been proposed that thrombosis risk in COVID-19 not only is explained by critical illness and respiratory failure, but also may be associated with pulmonary intravascular...
coagulopathy. The approximately twofold increased adjusted odds of PE among Black hospitalized COVID-19 patients observed in our study is in line with the observation in the general population without COVID-19 that Black Americans have a 67–104% higher age-sex adjusted rate of venous thromboembolism than White Americans. This is

Figure 1 Adjusted association between race and outcomes of hospitalized COVID-19 patients. Abbreviations: ARDS, acute respiratory distress syndrome; ICU, intensive care unit. Variables adjusted for in multivariate analysis were shown in the Supplemental Table 2. Patients with pre-existing ESRD were excluded in the analysis of acute kidney injury. Reference: White race.

Figure 2 Inflammatory marker levels and oxygen saturation on admission in Black and White hospitalized COVID-19 patients, stratified by age, sex, presence of acute kidney injury (AKI), and pulmonary embolism (PE). Abbreviations: AKI, acute kidney injury; PE, pulmonary embolism. Data were expressed as mean ± SEM. * * * denotes statistically significant difference between Black and White patients (p <0.05).
generally understood to be due to the fact that Black individuals may have had higher circulating levels of von Willebrand Factor and Factor VIII, which are shown to independently confer risk of venous thromboembolism.25,28 Furthermore, in our study, increased D-dimer levels were observed in Black patients regardless of age, sex, and comorbidities. This finding

Figure 3 Peak inflammatory marker levels in Black and White hospitalized COVID-19 patients, stratified by age, sex, presence of acute kidney injury (AKI), and pulmonary embolism (PE). Abbreviations: AKI, acute kidney injury; PE, pulmonary embolism. Data were expressed as mean ± SEM. Data included highest levels of D-dimer, C-reactive protein, erythrocyte sedimentation rate, ferritin, lactate dehydrogenase and absolute neutrophil count, and lowest level of absolute lymphocyte count. “*” denotes statistically significant difference between Black and White patients (p <0.05).

Table 3 Correlates of Inflammatory Marker Levels on Admission in Multivariate Regression Models

| Covariates                  | D-dimer | CRP     | ESR     | Ferritin | LDH     |
|-----------------------------|---------|---------|---------|----------|---------|
|                             | Std     | p-value | Std     | p-value  | Std     | p-value  | Std     | p-value  | Std     | p-value  |
| White race                  | 1       |         | 1       |         | 1       |         | 1       |         | 1       |         |
| Black race                  | 0.07    | 0.012*  | −0.007  | 0.809   | 0.12    | <0.001* | 0.09    | 0.001*  | 0.11    | <0.001* |
| Age                         | 0.10    | 0.002*  | 0.20    | <0.001* | 0.19    | <0.001* | 0.05    | 0.090   | −0.001  | 0.962   |
| Male                        | 1       |         | 1       |         | 1       |         | 1       |         | 1       |         |
| Female                      | 0.02    | 0.437   | −0.12   | <0.001* | 0.05    | 0.071   | −0.16   | <0.001* | −0.13   | <0.001* |
| BMI                         | 0.02    | 0.467   | −0.12   | <0.001* | 0.11    | <0.001* | −0.16   | <0.001* | −0.13   | <0.001* |
| Smoking history             | −       |         | −0.06   | 0.050*  | −       |         | −       |         | −0.08   | 0.006*  |
| Alcohol use                 | −       |         | −0.03   | 0.029   | −       |         | −       |         | −0.08   | 0.006*  |
| Type 2 diabetes             | −0.09   | 0.003*  | 0.08    | 0.010*  | 0.11    | <0.001* | −       |         | −0.08   | 0.015   |
| Hypertension                | −       |         | −0.10   | 0.005*  | −       |         | −       |         | −0.08   | 0.015   |
| Cerebrovascular disease     | 0.08    | 0.006*  | −       |         | −       |         | −       |         | −       |         |
| Asthma                      | −       |         | 0.02    | 0.429   | −       |         | −       |         | −       |         |
| COPD                        | −       |         | −0.03   | 0.387   | −       |         | −0.05   | 0.061   | −       |         |
| CKD                         | −       |         | 0.002   | 0.946   | 0.07    | 0.017*  | −       |         | −0.05   | 0.015   |
| ESRD                        | −       |         | 0.17    | <0.001* | −       |         | −0.05   | 0.015   | −       |         |
| Malignancy                  | −       |         | −0.02   | 0.530   | −       |         | −       |         | −       |         |
| HIV infection               | −       |         | 0.03    | 0.341   | −       |         | −       |         | −       |         |

Abbreviations: BMI body mass index, CKD chronic kidney disease, CRP C-reactive protein, ESR erythrocyte sedimentation rate, ESRD end-stage renal disease, HIV human immunodeficiency virus, Std β standardized β coefficient, LDH lactate dehydrogenase

“*” denotes statistically significant difference between Black and White patients (p <0.05)
For example, ACE2, IL-6, and AChE genes have been associated with higher COVID-19 disease burden and have been shown to be more prevalent in the Black population.45–48 Furthermore, Black individuals are at a higher risk for vitamin D deficiency. Vitamin D has been proposed to be protective against COVID-19 infectivity and severity as it modulates the immune system by suppressing T helper 1 immune profile and upregulating the regulatory T cell expression, thereby reducing the severity of cytokine storm.49–52 Therefore, Black patients may be at higher risk than White patients of cytokine storm and resulting systemic and intrarenal inflammation. This is also supported by the higher levels of inflammatory markers among Black patients observed in our study. Of particular interest is that, in our study, higher levels of inflammatory markers were also observed in Black patients with AKI compared with White patients with AKI.

Another potential explanation for racial differences in AKI is related to collapsing glomerulopathy predisposed by APOL1 high-risk allele. Approximately 14% of the Black population are homozygous for the G1 or G2 APOL1 risk alleles known to be strongly associated with focal segmental glomerulosclerosis and HIV-associated nephropathy.53,54 Similarly to that observed in the context of viral infections and conditions that upregulate levels of interferon, the systemic inflammatory response in COVID-19 is thought to interact with the APOL1 variant gene, leading to impairment in glomerular epithelial cell autophagy, mitochondrial function, and cell injury, thereby causing collapsing glomerulopathy and AKI with nephrotic-range proteinuria.55,56 This proposed mechanism is strengthened by the recent case series in six Black patients with APOL1 high-risk genotype who developed biopsy-proven collapsing glomerulopathy associated with COVID-19.56

This study has certain limitations that should be acknowledged. First, this is a retrospective study so there are inherent limitations in available information and/or documentation (e.g., laboratory data, comorbidities, and hospital outcomes).
Second, we extracted data from records of patients who were hospitalized between March and August 2020. Therefore, the treatment strategy in our study may not be representative of the most updated standard treatment for COVID-19. Third, higher rates of occult cardio-metabolic conditions and CKD have been observed in the Black populations. These conditions are also risk factors for PE and AKI. Although multivariate analysis was performed to adjust for recognized comorbidities including obesity, the apparent increased risks for PE and AKI might still be driven by the higher rates of undiagnosed underlying conditions in the Black population including hypertension and type 2 diabetes. Furthermore, we were unable to control for timing of presentation, which might also impact the effects of treatment for COVID-19 with remdesivir and/or dexamethasone. Therefore, some of the observed differences in clinical outcomes and inflammatory marker levels may be due to the difference in timing of presentation for care between Black and White patients. Additionally, data on staging of AKI including change of creatinine from baseline as well as quantification of proteinuria were not available for this study. Thus, we were unable to compare the severity of AKI between the two racial groups. It should also be noted that there is evidence suggesting that pulse oximetry is systematically less accurate in Black individuals. This may lead to bias in ascertainment of hypoxemia based on oxygen saturation measured by pulse oximetry. Finally, as our study focused only on hospitalized patients, the result may not be generalizable to the rest of the COVID-19 population.

Based on the results of our study along with others, it appears that the racial disparities in COVID-associated outcomes are due in part to pre-existing comorbidities and possibly other biologic variables that were not directly measured in this study such as vitamin D status, APOL1 genotype, or other immune phenotyping. Future studies are needed to study racial differences in such biologic factors to more clearly delineate causation. It is apparent from many prior studies that higher rates of infection, morbidity, and mortality among Black patients are due to socioeconomic factors as a by-product of systemic racism. Therefore, it is important to employ interventions to mitigate these disparities. Diagnosing occult comorbidities, aggressive risk factor modification, and providing health education around reducing COVID risk are critical. As vaccines enter the phases of community-wide rollout, promoting vaccine awareness and uptake among Black patients may help improve the clear health disparities. These will require the mutual inclusions and collaboration of local government, various organizations, policymakers, and researchers to mend healthcare in the populations disproportionately affected by COVID-19.

Equally important is that biologic risk factors that can be measured are increasingly likely to be responsible for many of the differences seen in prevalence of comorbidities and their morbidity and mortality among races. As research advances to uncover biologic and genetic influences, we as others find it prudent to report the disparities in outcome in the COVID-19 pandemic. In our study, we used self-reported race, a social construct, as the primary exposure variable despite its flaw as a variable to categorize differences in our population. Racism and social and economic disadvantage partially explain the health disparities seen in racial groups. There is also an urgent need to further define the biologic and genetic factors driving outcomes in COVID-19. Defining this difference in the case of COVID-19, an infection with high mortality, will help elucidate the contributors of social determinants of health and structural racism in COVID-19 health outcomes. As more information is gathered on COVID-19, the genetic, biologic, and social influences must be urgently addressed to investigate racial disparities in health outcomes.

CONCLUSION

In conclusion, this retrospective cohort study of Black and White COVID-19 patients revealed increased rates of in-hospital death, myocardial infarction, PE, and AKI for Black patients that could be accounted for by confounders (such as comorbidities). Only PE and AKI remained significantly associated with Black race. The increased risks of these conditions are likely driven by a combination of systemic racism that results in differences in occult underlying comorbidities and biologic variables that were not directly measured in this study such as clotting factors, vitamin D status, APOL1 high-risk allele, and immune phenotyping. Studies are needed to further investigate the presence and biological mechanisms of racial differences in inflammatory burden and clinical outcomes of COVID-19.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11606-021-06931-1.

Author Contribution We thank Arash Shirvani, PhD, MD, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Department of Medicine, Boston University School of Medicine, 85 E Newton St, M-1013, Boston, MA 02118, USA, who provided advice and assistance in statistical analysis.

Funding Nipith Charoenngam receives the institutional research training grant from the Ruth L. Kirchein National Research Service Award program from the National Institutes of Health (2 T32 DK 7201-42). Caroline M. Apovian is supported by P30 DK046200. Tiliayo O. Ilori is supported by a K23 career development grant from the National Institute of Diabetes and Digestive and Kidney Diseases (K23DK11954201). Natasha S. Hochberg is funded in part by a grant from the Warren Alpert Foundation and Boston University School of Medicine.

Conflicts of Interest: Michael F. Holick is a former consultant for Quest Diagnostics Inc., a consultant for Biogena Inc. and Ontometrics Inc.,
Respiratory Medicine. 2020;8(5):475-81. doi:https://doi.org/10.1016/S2213-2600(20)30079-5

36. Nimkar A, Naarasaay A, Hasan A, Pant S, Durdevic M, Suarez CN, et al. Incidence and Risk Factors for Acute Kidney Injury and Its Effect on Mortality in Patients Hospitalized From COVID-19. Mayo Clin Proc Innovations. Quality & Outcomes. 2020;4(6):687-95. doi:https://doi.org/10.1016/j.mayocpi.2020.07.003

37. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10221):497-506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5

38. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50. doi:https://doi.org/10.1016/j.dsx.2020.03.013

39. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 2020;318(6):F1454-F62. doi:https://doi.org/10.1152/ajprenal.00160.2020

40. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Explaining the racial difference in AKI incidence. J Am Soc Nephrol. 2020:CJN.09610620. doi:https://doi.org/10.2215/CJN.09610620

41. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16(6):308-10. doi:https://doi.org/10.1038/s41565-020-0284-7

42. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-18. doi:https://doi.org/10.1016/j.kint.2020.05.006

43. Bove B, Cai M, Xie Y, Gibson AK, Maddukuri G, Ali-Al Z, Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clinical Journal of the American Society of Nephrology. 2020;15(9):e237616. doi:https://doi.org/10.1136/jcnen.2020-237616

44. Grams ME, Matsushita K, Sang Y, Estrella MM, Foster MC, Tin A, et al. Explaining the racial difference in AKI incidence. J Am Soc Nephrol. 2014;25(8):1834-41. doi:https://doi.org/10.1681/ASN.2013080867

45. Phillips N, Park I-W, Robinson JR, Jones HP. The Perfect Storm: COVID-19 Health Disparities in US Blacks. J Racial Ethn Health Disparities. 2020:1-8. doi:https://doi.org/10.1007/s40615-020-00871-y

46. Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an em-in silico-em study. bioRxiv. 2020;2020.04.23.057042. doi:https://doi.org/10.1101/2020.04.23.057042

47. Slepnev N, Lewis TT, Gruenewald TL, Mujahid MS, Ryff CD, Albert MA, et al. Early life adversity and inflammation in African Americans and whites in the midlife in the United States survey. Psychosom Med. 2020;72(7):694-701. doi:https://doi.org/10.1097/PSY.000000000000146f

48. Vinciguerra M, Greco E. Sars-CoV-2 and black population: ACE2 as shield or blade? Infect Genet Evol. 2020;84:104361. doi:https://doi.org/10.1016/j.meegid.2020.104361

49. Holick MP. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81. doi:https://doi.org/10.1056/NEJMra070553

50. Kumar R, Rathi H, Haq A, Wimalawansa SJ, Sharma A. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. Virus Res. 2021;292:189235. doi:https://doi.org/10.1016/j.virusres.2020.189235

51. Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and Disease. Nutrients. 2020;12(7):2097. doi:https://doi.org/10.3390/nu12072097

52. Charoenngam N, Shrivani A, Holick MF. Vitamin D and Its Potential Benefit for the COVID-19 Pandemic. Endocr Pract. 2021:S1530-891X(21)00087-2. doi:https://doi.org/10.1016/j.jep.2021.03.006

53. Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nature Reviews Nephrology. 2020;16(10):565-7. doi:https://doi.org/10.1038/s41581-020-0332-3

54. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowen DW, et al. MH19 is a major effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2020;48(10):1175-84. doi:https://doi.org/10.1038/s41588-020-0626-8

55. Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D’Agati V, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 2015;87(2):332-42. doi:https://doi.org/10.1038/ki.2014.270

56. Wu H, Larsen CP, Hernandez-Arroyo CF, Mohamed MMB, Caza T, Shashir MD, et al. AKI and Collapsing Glomerulopathy Associated with COVID-19 and <em>em>APOL1</em><span class=&quot;sc&quot;><em>1</span> em>—</em> High-Risk Genotype. Journal of the American Society of Nephrology. 2020;31(8):1688. doi:https://doi.org/10.1681/ASN.2020050558

57. Graham G. Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev. 2015;11(3):238-45. doi:https://doi.org/10.2174/1573404138038615057042

58. Kim EJ, Kim T, Conigliaro J, Liebschutz JM, Paasche-Orlow MK, Feiner JR, Severinghaus JW, Bickler PE. Dark Skin Decreases the Accuracy of Pulse Oximeters at Low Oxygen Saturation: The Effects of Oximeter Probe Type and Gender. Anesthesia & Analgesia. 2007;105(6). doi:https://doi.org/10.1213/01.ANE.0000263995.1057042

59. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine. 2020;383(19):1813-26. doi:https://doi.org/10.1056/NEJMoct2027764

60. Ahmed MH, Hassan A. Dexmethylasone for the Treatment of Coronavirus Disease (COVID-19): a Review. SN Compr Clin Med. 2020:1-10. doi:https://doi.org/10.1007/s42399-020-00610-8

61. Feiner JR, Severinghaus JW, Bickler PE. Dark Skin Decreases the Accuracy of Pulse Oximeters at Low Oxygen Saturation: The Effects of Oximeter Probe Type and Gender. Anesthesia & Analgesia. 2007;105(6). doi:https://doi.org/10.1213/01.ANE.0000263995.1057042

Publisher’s Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.